期刊
DIABETES OBESITY & METABOLISM
卷 23, 期 1, 页码 263-269出版社
WILEY
DOI: 10.1111/dom.14203
关键词
antidiabetic drug; DPP-4 inhibitor; pharmaco-epidemiology; SGLT2 inhibitor; type 2 diabetes
资金
- MRC [MR/S003878/1] Funding Source: UKRI
- Medical Research Council [MR/S003878/1] Funding Source: Medline
The study found that during the COVID-19 pandemic, there was no increased risk of COVID-19 among individuals with type 2 diabetes prescribed SGLT2 inhibitors compared to those prescribed DPP-4 inhibitors.
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2 inhibitor prescription is associated with COVID-19, when compared with an active comparator. We performed a propensity-score-matched cohort study with active comparators and a negative control outcome in a large UK-based primary care dataset. Participants prescribed SGLT2 inhibitors (n = 9948) and a comparator group prescribed dipeptidyl peptidase-4 (DPP-4) inhibitors (n = 14 917) were followed up from January 30 to July 27, 2020. The primary outcome was confirmed or clinically suspected COVID-19. The incidence rate of COVID-19 was 19.7/1000 person-years among users of SGLT2 inhibitors and 24.7/1000 person-years among propensity-score-matched users of DPP-4 inhibitors. The adjusted hazard ratio was 0.92 (95% confidence interval 0.66 to 1.29), and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID-19 in primary care amongst those prescribed SGLT2 inhibitors compared to DPP-4 inhibitors, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID-19 pandemic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据